Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05553639 is registered in ClinicalTrials.gov with Hookipa Biotech GmbH as lead sponsor.

NCT NCT05553639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05553639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Hookipa Biotech GmbH
Phase
Phase 1/2
Overall status
Terminated
Start date
May 23, 2023
Completion date
April 29, 2024
Enrollment
12 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic